^™middle.

Gathering signals...

Zelira Therapeutics (ASX:ZLD) — Material Events

ASX:ZLD · 5 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed

Significant Score 75–89

4

Zelira Secures US$33M to Propel HOPE® 1 Autism Drug Through FDA TrialsHigh

Zelira raises US$33M with ThirdGate Capital for HOPE® 1 autism drug FDA trials

16 Jan 2026 ·Capital Raising ·85

Zelira Therapeutics Secures US$33M to Accelerate HOPE 1 FDA TrialsMedium

Zelira Therapeutics raises US$33M for HOPE 1 FDA trials, receives $1.07M R&D refund

29 Jan 2026 ·Quarterly Activities Report and Appendix 4C ·85

Zelira Therapeutics Secures US$33M Fundraising to Propel HOPE® 1 FDA TrialsMedium

Zelira Therapeutics secures US$33M fundraising to advance HOPE® 1 FDA trials amid operational cash outflows

30 July 2026 ·Quarterly Activities Report and Appendix 4C ·85

Zelira Advances HOPE 1 FDA Trials, Secures $650k R&D Loan Amid Cash BurnMedium

Zelira advances HOPE 1 FDA trials, secures $650k R&D loan, reports $711k cash burn in Q1 FY2026

27 Oct 2025 ·Quarterly Activities Report and Appendix 4C ·75

Notable Score 50–74

1

Zelira Therapeutics Secures $1.07M R&D Refund to Boost Clinical PipelineMedium

Zelira Therapeutics receives $1.07M R&D tax refund to fund clinical and product development

25 Nov 2025 ·ASX Announcement ·70

Not Assessed Low Score, or missing data

0

No articles in this tier for the last 12 months.

Market Mentions 3 - appeared in market wrap coverage

These are market wrap articles where Zelira Therapeutics (ASX:ZLD) was mentioned. They reflect broader market coverage, not company-specific announcements.

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026

Market Wrap - Week 3 (12 Jan -> 16 Jan) 2026